The main purpose of Complamina (Xantinol Nicotinate) is to provide symptomatic relief in conditions caused by poor or inadequate blood circulation, and is relevant for easing disruptive symptom manifestations. The compound is primarily used as a peripheral vasodilator agent.

---

What Complamina Treats: Main Uses and Benefits

Complamina is commonly used across conditions characterized by periods of heightened symptoms that may appear suddenly or intensify over time. The medication helps address symptom clusters that may become intense or disruptive, particularly those related to Peripheral Vascular Disease and Cerebral Insufficiency.

These primary therapeutic domains involve supporting the management of symptoms such as leg pain and cramping associated with walking, persistent coldness or numbness in the extremities, dizziness and vertigo, and difficulties with concentration—symptoms that create noticeable physiological strain. Applied in addressing these symptom clusters, the medication provides support that helps ease the overall symptom burden and contributes to general well-being during symptomatic periods.

“This medication is considered relevant in clinical settings where supportive symptom management for symptoms of restricted blood flow is appropriate.”

Its use is also relevant in specialized contexts requiring additional supportive assistance for microcirculatory issues, such as functional impairment associated with Oral Submucous Fibrosis. The medication may be part of symptomatic management and offers supportive relief within challenging symptomatic phases.

Quick Fact: Management of Symptoms Related to Physical Discomfort

Eligibility Map: Who can and cannot use Complamina

The eligibility profile for Complamina (Xantinol Nicotinate) is defined by official constraints and contraindications listed in regulatory documents.

---

Eligibility Scope

Classification	Restricted Population/Condition
Contraindicated	Acute Myocardial Infarction, Severe Arterial Bleeding, Known Hypersensitivity to Xantinol Nicotinate, Active Peptic Ulcer Disease.
Not Recommended	Pregnancy and Breastfeeding (Use is generally restricted unless deemed absolutely necessary by a physician).
Conditional Use	Patients with Hepatic Impairment, Renal Impairment, or severe Hypotension must be monitored closely; use in Mitral Stenosis requires caution.

---

Regulatory Status

• Age-Related Eligibility: The medicine is established for use in adults and adolescents over 18 years of age. Use in younger children is generally noted in labeling as not established.
• Comorbidity Limitations: Caution is necessary in patients with underlying conditions such as low blood pressure, bleeding disorders, and gout.

Regulatory documentation establishes these constraints to formally prohibit use in patients with critical cardiovascular or hemorrhagic statuses and to mandate caution in patients with specific chronic organ and disease limitations.

Complamina Interactions with other medicines and products

The interaction profile for Xantinol Nicotinate (Complamina) is defined primarily by its function as a peripheral vasodilator, which creates a risk of additive pharmacological effects when co-administered with certain substance classes.

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Antihypertensive Medicines; Other Vasodilators and Nitrates.
Specific interacting medicines (if explicitly listed)	Lisinopril, Amlodipine, Isosorbide Mononitrate.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic reinforcement (additive vasodilatory activity).
Interaction-related restrictions	Substance restriction: Alcohol consumption (may increase risk of hypotension).

---

Interaction classifications (high-level)

Classification	Official Regulatory Documentation Statement
Interaction severity classification (as defined in official documents)	Interactions classified by the risk of additive hypotension.
Interaction-context constraints (as defined in official documents)	Co-administration must consider the pharmacodynamic risk of blood pressure lowering.

---

Official interaction statements:

• Co-administration with Antihypertensive Medicines may result in a pharmacodynamic reinforcement of the blood pressure-lowering effect, increasing the risk of hypotension (low blood pressure).
• The use of Complamina with Other Vasodilators and Nitrates is documented to potentially lead to additive vasodilatory activities.
• Consumption of Alcohol is noted to increase the substance interaction risk, contributing to the possibility of hypotension.
• No specific drug-drug combinations are formally labeled as contraindicated combinations in available regulatory summaries.

Connection to the overall interaction profile Regulatory documentation defines the interaction structure of Complamina primarily through pharmacodynamic interactions, where its core function as a peripheral vasodilator creates an additive effect with agents that lower blood pressure. The official profile explicitly details this reinforcement with antihypertensive and vasodilatory drug classes, alongside a specific restriction regarding the co-consumption of alcohol, with all interactions linked to the formal outcome of increased hypotension risk. This structure excludes any explicit mention of metabolic, transporter-based, timing-dependent, or population-specific interaction constraints in official labeling.

The mechanism of Xantinol Nicotinate involves a dual molecular action that simultaneously modulates blood vessel tone and influences the physical properties of blood flow.

Dual Pathway Modulation of Vascular Tone

This action targets the smooth muscle surrounding blood vessels via two distinct pathways: inhibition of Phosphodiesterase ( PDE) enzymes and activation of specific G-protein coupled receptors ( GPR109A) by the Nicotinic Acid moiety. This molecular action raises intracellular levels of cyclic AMP ( cAMP) and stimulates the release of Prostaglandins, which drive the relaxation of vascular smooth muscle, contributing to a systemic decrease in vascular resistance.

---

Modulation of Hemorheology and Microcirculatory Potential

This domain details the drug's influence on the blood components themselves. By inhibiting PDE within platelets and modulating the energy metabolism of red blood cells ( RBCs), the drug decreases the blood's viscosity and supports increased RBC flexibility. This rheological change influences the capacity for flow through the smallest capillaries, leading to a molecular and physiological basis for increased tissue perfusion and oxygen availability.

---

Mechanistic Constraints: Non-Selective Target Engagement

The mechanism involves non-selective antagonism of Adenosine Receptors ( A1/ A 2A) and broad PDE inhibition, leading to widespread target engagement across the vascular system. This non-selective profile introduces the physiological constraint of the "vascular steal" phenomenon, where flow may be diverted away from maximally diseased areas due to preferential dilation of healthier vessels.

How to Use Complamina (Xantinol Nicotinate) — Administration Guidelines

Complamina (Xantinol Nicotinate) is used according to established administration guidelines, which define the approved route, dosage, and intake conditions.

Administration Scope

Feature	Labeled Instruction
Route of Administration	Oral (tablet, sustained-release tablet); Intravenous (IV) injection (clinical use only)
Standard Dosing	150 mg or 300 mg oral tablets; 500 mg or 1 g sustained-release tablets (Retard SR). The exact dose is determined by the prescribing professional.
Frequency	Typically 2 to 3 times per day for standard tablets, or 2 times per day for sustained-release tablets.
Timing in Relation to Meals	Recommended to be taken with food or after meals to reduce the potential for gastrointestinal upset.
Tablet Handling	Tablets, especially sustained-release forms, must be swallowed whole with water. They should not be chewed, crushed, or broken.

Procedural and Population Rules

Age-Group Rules: Use in elderly patients and children requires caution and possible dose adjustments determined by a healthcare professional.

Missed-Dose Protocol: If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped, and the regular dosing schedule should be resumed. Do not take a double dose.

Administration Constraints: The injection formulation must only be administered by qualified healthcare personnel in a controlled setting. Dose adjustments may be necessary for patients with impaired renal or hepatic function.

These instructions constitute the standardized protocol for the correct use of Complamina.

Research evidence / Overview of studies for Complamina

Evidence for use in Peripheral Vascular Disease and Chronic Lower Limb Ischemia

Research was evaluated in conditions characterized by fluctuating or episodic manifestations such as Peripheral Vascular Disease (PVD) and lower limb ischemia. Studies were observed in populations with severe vessel blockages. These studies included controlled clinical trials and observational settings. The research primarily monitored short-term symptom patterns and measured outcomes related to physical discomfort and functional changes.

Researchers examined specific objective measures like walking distance (claudication distance) and blood flow indicators like the Ankle-Brachial Pressure Index (ABPI). Studies reported measurements related to blood flow characteristics and changes in functional capacity, such as walking distance data. Findings describe patterns observed in the studies over the short-term trial duration, and older research provides insight into short-term changes.

Evidence for use in managing symptoms of Cerebrovascular Disorders

The compound was studied for its use in conditions involving periods of heightened symptoms related to cerebrovascular disorders. The evidence base includes older controlled double-blind clinical trials and subsequent drug monitoring studies. Research explored short-term symptom changes, focusing on episodes where symptoms become more noticeable.

Studies examined outcomes related to systemic or functional imbalance, such as patient-reported outcomes describing perceived discomfort like dizziness, fatigue, and difficulty concentrating. Research also monitored performance on cognitive function tasks (like memory tests) over defined time intervals. Findings describe patterns observed in the studies related to these symptomatic changes, primarily in the older adult (geriatric) population.

Areas of Uncertainty and Research Gaps

A significant portion of the evidence base relies on older controlled trials, meaning that the evidence quality varies across studies compared to modern standards. Key limitations include the fact that sample sizes were modest in many trials, and follow-up durations were limited, especially regarding long-term maintenance outcomes. For Oral Submucous Fibrosis (OSMF), the research is primarily associated with a localized administration route, which means that evidence for the compound’s systemic administration in this condition is limited. Overall, there is limited information to provide comprehensive evidence across all registered uses.

Key Studies & References

1. Evaluation of efficacy of intralesional Xantinol Nicotinate in the treatment of OSMF (Yadav T, et al., 2022)

Common questions about Complamina (FAQ)

Q: Does Complamina help with blood circulation issues?

According to official product information, Complamina is indicated for use in managing conditions such as peripheral vascular disease and certain cerebrovascular disorders. The medicine is described as working to widen blood vessels (a process called vasodilation), which is intended to improve overall blood flow.

Q: How does Complamina fit into the general class of vasodilators?

Complamina is chemically a derivative of theophylline and niacin (Vitamin B3). It is classified in regulatory documents as a peripheral vasodilator, meaning it acts to relax and widen blood vessels, primarily in the extremities.

Q: Can Complamina cause stomach upset or nausea?

Yes, regulatory information lists gastrointestinal disturbances, including stomach upset and nausea, as potential side effects. Official product labeling advises that the medicine is taken with food or after meals to help reduce this possibility.

Q: Does Complamina have any known effects on liver function?

Official documentation indicates that caution is necessary when Complamina is used by patients with a history of liver problems. Dose adjustments or specific monitoring may be considered by a healthcare professional.

Q: What is the purpose of the 'nicotinate' part of the active ingredient?

The active ingredient, Xantinol Nicotinate, is a chemical compound containing both xantinol and nicotinic acid. The nicotinic acid component is released through metabolism and contributes to the drug's effect of widening blood vessels.

Q: Are there certain age groups where Complamina is not recommended?

The medicine is generally intended for use by adults. Regulatory guidance advises that its use in both elderly patients and children requires caution and possible dose adjustments, which are determined by a professional.

Q: Is Complamina a type of vitamin or a prescription medicine?

Complamina is classified as a prescription-only medicine. While its active ingredient, Xantinol Nicotinate, is a chemical derivative of niacin (a type of B vitamin), it is regulated as a pharmaceutical drug.

Q: How quickly should I expect to feel any effects from Complamina?

Official product information does not specify an exact time frame for when effects should be felt. It is described as beginning to improve blood flow soon after administration, but the duration of treatment will vary by individual need.

Q: What is Complamina prescribed for most often?

According to its regulatory approvals, Complamina is primarily prescribed for conditions involving impaired blood circulation. These include peripheral vascular disease and certain cerebrovascular disorders.

Q: Is it normal to feel a flushing or warming sensation after taking Complamina?

Yes, official product information lists flushing—a sensation of warmth, redness, or tingling—as one of the most common side effects. This sensation is related to the drug's effect of widening blood vessels.

Q: Are there any common foods or drinks I should avoid while using Complamina?

Official product information states that the medicine is to be taken with food or after meals to help reduce the potential for stomach upset. No specific foods are universally prohibited by regulatory documents.

Q: Can Complamina be used for long-term health maintenance?

Complamina is often prescribed for long-term use to help manage the chronic symptoms of conditions like peripheral vascular disease. The need for regular follow-up appointments may be determined to monitor effectiveness and potential adjustments.

Q: What kind of research has been done on Complamina?

Research related to Complamina often focuses on its effects in areas of poor blood circulation. Studies have examined its utility for peripheral vascular disease, as well as cerebrovascular insufficiency and related symptoms of memory or concentration.

Q: Can Complamina affect my ability to drive or operate machinery?

Caution is advised by regulatory documents regarding activities such as driving or operating machinery. Side effects like dizziness or headache are known to occur and could potentially affect a person's ability to concentrate.

Q: Is it possible to become dependent on Complamina?

Official fact sheets and regulatory documentation generally indicate that Complamina is not classified as a habit-forming or addictive substance.

Q: What happens if I stop using Complamina suddenly?

Regulatory patient advice indicates that if treatment is discontinued too early, the symptoms of the original condition being treated may return or worsen.

Q: Why do some people experience dizziness as a side effect?

Dizziness is a reported side effect that can occur with use. It is thought to be related to the drug's action as a vasodilator, which can influence blood pressure.

Q: Is Complamina available over-the-counter in some countries?

Complamina is generally classified as a prescription-only medicine in most countries where it is approved. The regulatory status can be specific to each country.

Q: What conditions make someone ineligible to use Complamina?

Official contraindications list several conditions that make use inappropriate. These include known hypersensitivity, severe heart conditions (like recent heart attack), arterial bleeding, and active peptic ulcer disease.

Q: Does Complamina carry a high risk of drug-to-drug interactions?

Official documents advise caution regarding certain combinations. For instance, Complamina may enhance the effects of blood-thinning medications, such as anticoagulants or antiplatelet drugs.

Q: What is the duration of action for a typical dose of Complamina?

The specific duration of action for a single dose is not universally defined in regulatory information. Treatment duration is managed by a physician based on the specific condition being treated.

Q: Are the side effects of Complamina generally mild or severe?

Most of the common side effects listed, such as flushing and headache, are described as temporary. Official information states that these effects generally resolve over time with continued use.

Q: Can Complamina be taken if I have a history of ulcers?

Official contraindications state that Complamina should not be used by individuals who have active peptic ulcer disease.

Q: Is there a summary of the clinical trial evidence for Complamina's effectiveness?

Clinical studies summarized in regulatory documents indicate the medicine's utility for managing symptoms of peripheral vascular disease. Research also suggests it may aid symptoms associated with certain cerebrovascular issues.

Q: Does Complamina affect blood pressure levels?

Yes, the drug is a vasodilator, meaning it widens blood vessels. This action can potentially affect blood pressure levels, and dizziness resulting from lower blood pressure is a possible side effect.

Q: What are the official approved uses for Complamina?

Official approved uses are focused on treating conditions involving impaired circulation. These include peripheral vascular disease and specific cerebrovascular disorders.

Q: Is it true that Complamina has been used for memory or cognitive issues?

Studies have examined Complamina’s use in the context of cerebrovascular disorders, which may involve symptoms related to concentration, memory, and awareness. The drug's intended use is tied to improving blood flow in these areas.

Q: What if I have an allergic reaction to Complamina?

Official guidance states that the drug is contraindicated for use by individuals who have a known hypersensitivity or allergy to Xantinol Nicotinate or its components.

Q: Are there specific storage requirements for Complamina tablets or injections?

Regulatory information generally advises that the medicine should be stored in a cool, dry place. It should be kept away from direct sunlight to maintain its quality and stability.

Q: How is Complamina different from niacin (nicotinic acid)?

Complamina is a derivative compound of niacin (Vitamin B3). While chemically related, Complamina releases niacin as one of its active components when it is broken down by the body.

Q: How long does the flushing side effect usually last?

The flushing sensation is generally temporary. Official product information indicates that most common side effects are expected to resolve gradually over time, especially with continued use.

Q: What types of heart conditions are listed as contraindications for Complamina?

Official contraindications list severe heart conditions, including recent myocardial infarction (heart attack), as conditions for which the drug should not be used.

Q: Can Complamina be taken by people with diabetes?

Official documentation advises that caution is necessary when Complamina is used by patients with diabetes. Any management regarding the potential impact on blood sugar levels is determined by a healthcare provider.

Q: How is the patient experience with Complamina generally described in studies?

Some studies have noted that patients who experience significant benefit from the medicine are often more accepting of common side effects like flushing. This information comes from clinical observation reports.

Q: What information is available about Complamina use during pregnancy or breastfeeding?

Regulatory guidance advises that individuals who are pregnant or breastfeeding should only use this medicine after consulting a doctor. The professional will weigh the potential risks and benefits.

Q: Are there any known interactions between Complamina and alcohol?

Regulatory documents state that limiting or avoiding alcohol may be necessary, as alcohol could increase the risk of side effects such as low blood pressure or severe flushing.

Q: Why is it important to tell my doctor about all the medicines I take while using Complamina?

It is important to disclose all medications because Complamina may affect the actions of other drugs. For instance, it is known to potentially increase the effects of anticoagulants or antiplatelet medicines.

Q: Does the efficacy of Complamina decrease over time with continued use?

Complamina is often prescribed for long-term management of chronic conditions. Monitoring of the long-term efficacy and progress through regular follow-up appointments may be indicated.

Q: What is the most frequently reported side effect of Complamina?

The most frequently reported side effect in official documents is flushing. This is described as a warm sensation, redness, or tingling, typically in the face, neck, and trunk.

Q: Is Complamina a controlled substance?

Official fact sheets generally indicate that Complamina is not considered a habit-forming drug and is not typically classified as a controlled substance.

Q: What does 'peripheral vascular disorder' mean in the context of Complamina?

Peripheral vascular disorder is a general term for a condition where blood vessels are narrowed or blocked, restricting blood flow, often to the limbs. Complamina is intended to help improve circulation in these areas.

Q: Is Complamina a blood thinner?

Complamina is primarily classified as a vasodilator (blood vessel widener). While clinical reports indicate it may help reduce blood viscosity (thickness), it is not typically categorized as a blood thinner, such as an anticoagulant or antiplatelet drug.

Q: What is the general safety profile of Complamina according to official reports?

The general safety profile is described in regulatory documents by the list of known side effects and contraindications. Common side effects are generally temporary, and use is prohibited in patients with certain severe pre-existing conditions.

How to Store and Dispose of Complamina

Complamina (Xantinol Nicotinate) must be stored according to official labeling to maintain its stability.

Storage Requirements

• Temperature: Store tablets below 30 C and the injection solution below 25 C.
• Environmental Protection: The product must be kept in a dry place, stored in its original container, and protected from light and moisture.
• Child Safety: It is mandatory to keep the medicine out of the sight and reach of children.

Disposal

Unused or expired Complamina should not be flushed down a toilet or sink. The product must be discarded by mixing it with an unappealing substance, sealing it in a container, and placing it in household trash, following general federal guidelines. Any used needles or syringes from the injection form must be immediately placed in an FDA-cleared sharps disposal container.